ALKS Alkermes plc.

Did the company actually spend money buying back stock in 3+ of the last 4 quarters?

Bought back stock in 2/2 quarters. Q3 2024: $116M, Q3 2025: $116M

Is the most recent quarter's buyback spend more than 15% above the trailing average?

Latest quarter $116M vs trailing avg $116M (+0%)

What percentage of free cash flow is going to buybacks? Bull: 30-80%. Bear: <10% or >80%.

Negative FCF ($-117M), cannot compute buyback ratio

How fast are they shrinking the float? Bull: 2%+ annually. Bear: under 0.5%.

Repurchased 15,800,000 shares = 9.7% of 162,176,994 outstanding (annualized)

Are officers and directors buying stock with their own money on the open market?

1 open-market purchase by Daglio David Angelo Jr.

• Daglio David Angelo Jr. () bought 35,000 shares at $23.31 on 2022-11-14

Are insider purchases happening during the same quarters the company is actively buying back stock?

Insider buying coincided with company buybacks in 0 of 2 quarters

Looking at all open-market transactions, are insiders net buyers or net sellers?

Insiders bought $1M, sold $27M (net selling)

Active buyback + insiders net selling 3x+ more than buying. Company cash may be supporting price while insiders exit.

Company buying back stock while insiders sold 33.7x more than bought. 2 C-suite officers among sellers

• Nichols Christian Todd (SVP, Chief Commercial Officer) sold 6,000 shares on 2026-03-02
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares on 2026-03-02
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 5,000 shares on 2026-02-02
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 4,000 shares on 2026-02-02
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 5,000 shares on 2026-01-08
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 4,000 shares on 2026-01-02
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 3,748 shares on 2025-12-03
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 4,000 shares on 2025-12-01
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares on 2025-11-03
• Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares on 2025-10-15